Abstract

The recent publication of a systematic review and meta-analysis of published and unpublished data from controlled trials on the effects of reboxetine in the acute treatment of major depression (Eyding et al, 2010) has reignited the debate surrounding the publication of negative trials by pharmaceutical companies.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call